BR112021022784A2 - Composições e métodos para tratamento do câncer - Google Patents
Composições e métodos para tratamento do câncerInfo
- Publication number
- BR112021022784A2 BR112021022784A2 BR112021022784A BR112021022784A BR112021022784A2 BR 112021022784 A2 BR112021022784 A2 BR 112021022784A2 BR 112021022784 A BR112021022784 A BR 112021022784A BR 112021022784 A BR112021022784 A BR 112021022784A BR 112021022784 A2 BR112021022784 A2 BR 112021022784A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- cancer treatment
- treating cancer
- referenced
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
composições e métodos para tratamento do câncer referência remissiva a pedidos relacionados. a presente invenção fornece métodos para o tratamento do câncer
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962847570P | 2019-05-14 | 2019-05-14 | |
PCT/US2020/032847 WO2020232227A1 (en) | 2019-05-14 | 2020-05-14 | Compositions and methods for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021022784A2 true BR112021022784A2 (pt) | 2022-03-22 |
Family
ID=73245256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021022784A BR112021022784A2 (pt) | 2019-05-14 | 2020-05-14 | Composições e métodos para tratamento do câncer |
Country Status (12)
Country | Link |
---|---|
US (1) | US11534420B2 (pt) |
EP (1) | EP3968785A4 (pt) |
JP (1) | JP2022532210A (pt) |
KR (1) | KR20220098682A (pt) |
CN (1) | CN114173578A (pt) |
AU (1) | AU2020276605A1 (pt) |
BR (1) | BR112021022784A2 (pt) |
CA (1) | CA3140042A1 (pt) |
EA (1) | EA202193111A1 (pt) |
IL (1) | IL287982A (pt) |
MX (1) | MX2021013901A (pt) |
WO (1) | WO2020232227A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2021013901A (es) | 2019-05-14 | 2022-04-12 | Tyme Inc | Composiciones y métodos para el tratamiento del cáncer. |
CN114599352A (zh) * | 2019-10-15 | 2022-06-07 | 迪美公司 | 用于治疗癌症的α-甲基-DL-酪氨酸烷基酯 |
CA3167918A1 (en) * | 2020-01-17 | 2021-07-22 | Tyme, Inc. | Compositions and methods for modulating cancer |
US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
JP2023553011A (ja) * | 2020-12-02 | 2023-12-20 | ホフマン・テクノロジーズ・エルエルシー | 非ヒト哺乳動物においてがんを調節するための組成物および方法 |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029547A (en) | 1974-07-01 | 1977-06-14 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Biologically active substance, bestatin, and production thereof |
US4165382A (en) | 1977-10-17 | 1979-08-21 | Jose Pozuelo | Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine |
US4117161A (en) | 1977-05-16 | 1978-09-26 | Jose Pozuelo | Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine |
US4389415A (en) | 1978-01-24 | 1983-06-21 | Merck & Co., Inc. | Method of treating hypertension |
US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
GB8706313D0 (en) | 1987-03-17 | 1987-04-23 | Health Lab Service Board | Treatment & prevention of viral infections |
DE8907335U1 (pt) | 1989-06-15 | 1990-10-18 | Espe Stiftung & Co Produktions- Und Vertriebs Kg, 8031 Seefeld, De | |
IE62410B1 (en) | 1989-06-30 | 1995-01-25 | Richter Gedeon Vegyeszet | Process for the resolution of threo-3-[(2-aminophenyl)-thio]-2-hydroxy-3-(4-Methoxy- phenyl) propionic acid |
US5029760A (en) | 1989-10-26 | 1991-07-09 | Gamblin Rodger L | Centrifugal grinding and mixing apparatus |
JPH03161442A (ja) | 1989-11-21 | 1991-07-11 | Chiyouseidou Seiyaku Kk | コール酸又はそのナトリウム塩からなる脳代謝改善剤 |
US5225435A (en) | 1990-05-18 | 1993-07-06 | Yale University | Soluble melanin |
US5310539A (en) | 1991-04-15 | 1994-05-10 | Board Of Regents, The University Of Texas System | Melanin-based agents for image enhancement |
EP0648114B1 (de) | 1992-07-08 | 1997-09-17 | DIANORM G. Maierhofer GmbH | Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels |
DE4342174C1 (de) | 1993-12-10 | 1995-05-11 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung |
JP2000507938A (ja) | 1996-03-22 | 2000-06-27 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 結腸直腸の化学的保護のためのウルソデオキシコール酸化合物及びnsaidの組合せ |
US5733926A (en) | 1996-12-13 | 1998-03-31 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
IT1291633B1 (it) | 1997-04-22 | 1999-01-11 | Pharmaconsult S A S | Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride |
US5929055A (en) | 1997-06-23 | 1999-07-27 | The Research Foundation Of State University Of New York | Therapeutic method for management of diabetes mellitus |
US5952374A (en) | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
CA2341903A1 (en) | 1998-08-21 | 2000-03-02 | The Children's Medical Center Corporation | Use of melanin for inhibition of angiogenesis and macular degeneration |
DE19906977C1 (de) | 1999-02-19 | 2000-06-15 | Lohmann Therapie Syst Lts | Desoxypeganin-TTS und seine Verwendung |
JP2002196006A (ja) | 2000-12-27 | 2002-07-10 | Olympus Optical Co Ltd | 自動分析装置 |
EP1363627A2 (en) | 2001-02-19 | 2003-11-26 | Novartis AG | Treatment of solid tumours with rapamycin derivatives |
WO2002098403A1 (en) | 2001-06-01 | 2002-12-12 | Georgetown University | Steroid hormone and non-steroidal anti-inflammatory drug combinations for inducing tumor cell apoptosis |
JP4609875B2 (ja) | 2001-07-31 | 2011-01-12 | 有限会社大長企画 | 健康食品 |
US7338971B2 (en) | 2001-08-30 | 2008-03-04 | El-Naggar Mawaheb M | Treatment of inflammatory, cancer, and thrombosis disorders |
US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
JP4091557B2 (ja) | 2003-03-18 | 2008-05-28 | 株式会社マンダム | 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品 |
WO2005072706A2 (en) | 2004-01-29 | 2005-08-11 | Baxter International Inc. | Nanosuspensions of anti-retroviral agents for increased central nervous system delivery |
EP3075247B1 (en) | 2004-02-02 | 2022-10-12 | BioSight Ltd. | Conjugates for cancer therapy and diagnosis |
EP1674081A1 (de) | 2004-12-23 | 2006-06-28 | KTB Tumorforschungsgesellschaft mbH | Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge |
WO2006099685A1 (en) | 2005-03-24 | 2006-09-28 | Medical Therapies Limited | Method for the prophylaxis or treatment of carcinomas |
AU2006229840B2 (en) | 2005-03-25 | 2010-12-23 | Merck Sharp & Dohme Corp. | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor |
US20060223877A1 (en) | 2005-03-31 | 2006-10-05 | Zemlan Frank P | Methods of treatment utilizing certain melatonin derivatives |
EP1909772A4 (en) | 2005-08-05 | 2011-07-13 | Nuvo Res Inc | TRANSDERMAL DRUG FORMULATION |
DK1961418T3 (da) | 2005-11-15 | 2012-07-23 | Cheng Jingcai | Anvendelse af isothiocyanatforbindelser til behandling af prostatasygdomme og hudcancer |
CN101516899B (zh) | 2006-04-19 | 2016-07-06 | 得克萨斯大学体系董事会 | 细胞成像和治疗的组合物和方法 |
EP1884243A1 (en) | 2006-05-02 | 2008-02-06 | Charité - Universitätsmedizin Berlin | Use of an antipsychotic drug for the treatment of ALS-associated cachexia |
CN101138634A (zh) | 2006-09-07 | 2008-03-12 | 于保法 | 用于***的组合物 |
US20100239661A1 (en) | 2006-10-26 | 2010-09-23 | Sunilendu Bhushan Roy | Pharmaceutical compositions of ursodiol |
US9198965B2 (en) | 2008-06-13 | 2015-12-01 | Wisconsin Alumni Research Foundation | Peptide adjuvant for influenza vaccination |
EP2208497A1 (en) | 2009-01-15 | 2010-07-21 | Charité-Universitätsmedizin Berlin (Charité) | Use of Ursodeoxycholic acid (UDCA) for enhancing the general health condition of a tumor patient |
US20170029892A1 (en) | 2009-05-29 | 2017-02-02 | Jay L. Lombard | Methods and compositions for the treatment of post-traumatic stress disorder |
EP2456869A4 (en) | 2009-07-23 | 2013-11-27 | Trustees Of The University Of Princeton | MTOR KINASE HEMMER AS ANTIVIRUS AGENT |
CN102753162A (zh) * | 2009-10-22 | 2012-10-24 | 南加利福尼亚大学 | 增加癌症治疗的效力和降低副作用的方法和营养配方 |
WO2011053835A1 (en) | 2009-10-30 | 2011-05-05 | Aton Pharma, Inc. | Stereoselective synthesis of metyrosine |
KR101131675B1 (ko) | 2010-01-28 | 2012-03-28 | 조선대학교산학협력단 | 우루소데옥시콜린산을 유효성분으로 함유하는 위암의 예방 또는 치료용 조성물 |
JP2013527155A (ja) | 2010-04-16 | 2013-06-27 | ダボス ライフ サイエンス ピーティーイー. リミテッド | 皮膚科用途のための少なくとも1つのビタミンe成分およびチロシナーゼ阻害剤の相乗的相互作用 |
GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
US9949923B2 (en) | 2011-03-15 | 2018-04-24 | Optinose As | Nasal delivery |
PL220308B1 (pl) | 2011-06-03 | 2015-10-30 | Kobel Buys Krystyna | Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego |
CN102397550B (zh) | 2011-08-30 | 2013-05-08 | 广东医学院 | 一组由阿司匹林与***组成的防治骨质疏松症的药物组合物 |
WO2013061161A2 (en) | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
WO2013096870A1 (en) | 2011-12-22 | 2013-06-27 | Knopp Neurosciences Inc | Compositions and methods for treating amyotrophic lateral sclerosis |
CN104039327B (zh) | 2012-01-06 | 2017-02-15 | 大熊制药株式会社 | 含有牛磺熊去氧胆酸的组合物 |
US8481498B1 (en) | 2012-01-17 | 2013-07-09 | Steven Hoffman | Pharmaceutical compositions and methods |
US20130183263A1 (en) | 2012-01-17 | 2013-07-18 | Steven Hoffman | Pharmaceutical compositions and methods |
US10272068B2 (en) | 2012-01-17 | 2019-04-30 | Tyme, Inc. | Pharmaceutical compositions and methods |
US20210386832A1 (en) | 2012-01-17 | 2021-12-16 | Tyme, Inc. | Pharmaceutical Compositions And Methods |
PL2804599T3 (pl) * | 2012-01-17 | 2019-06-28 | Tyme, Inc. | Terapia skojarzona do leczenia nowotworu złośliwego |
US10646552B2 (en) | 2012-01-17 | 2020-05-12 | Tyme, Inc. | Pharmaceutical compositions and methods |
WO2013142490A2 (en) | 2012-03-20 | 2013-09-26 | Metselex, Inc. | Tauroursodeoxycholic acid attenuates or abolishes formation and deposition of amyloid-b peptide |
US9962362B2 (en) | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
GB201216800D0 (en) | 2012-09-20 | 2012-11-07 | Immodulon Therapeutics Ltd | Novel use |
US11419922B2 (en) | 2012-11-16 | 2022-08-23 | Eric Finzi | Treatment of post-traumatic stress disorder using botulinum toxin A |
US9872865B2 (en) | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
KR20160030162A (ko) | 2013-07-11 | 2016-03-16 | 가부시키가이샤 폴라 파마 | 사용시 거품상을 나타내는 외용 조성물 |
US9724657B2 (en) | 2013-10-22 | 2017-08-08 | Tyme, Inc. | High-speed centrifugal mixing devices and methods of use |
US20150111878A1 (en) | 2013-10-22 | 2015-04-23 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
US9585841B2 (en) * | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
US9326962B2 (en) | 2013-10-22 | 2016-05-03 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
US20170080093A1 (en) | 2013-10-22 | 2017-03-23 | Tyme, Inc. | Tyrosine Derivatives And Compositions Comprising Them |
CN103919787A (zh) | 2014-04-17 | 2014-07-16 | 厦门大学 | 牛磺熊脱氧胆酸及其可接受的盐的制药用途 |
WO2016007741A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of California | Tumor selective macropinocytosis-dependent rapidly internalizing antibodies |
US11701369B2 (en) | 2014-09-28 | 2023-07-18 | Huahui Health Ltd. | Polymeric bile acid derivatives inhibit Hepatitis B and D virus and NTCP transport |
GB201419257D0 (en) | 2014-10-29 | 2014-12-10 | Jagotec Ag | Pharmaceutical compositions |
BR112017013329A2 (pt) | 2014-12-23 | 2019-09-03 | Hoffman Steven | composição e uso de uma composição |
US9687528B2 (en) | 2014-12-23 | 2017-06-27 | Steven Hoffman | Transdermal formulations |
CN106031731A (zh) | 2015-03-18 | 2016-10-19 | 中国医学科学院基础医学研究所 | 牛磺熊去氧胆酸的新用途 |
CA2982442A1 (en) | 2015-04-14 | 2016-10-20 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
US20170181993A1 (en) | 2015-12-28 | 2017-06-29 | Steven Hoffman | Methods of Treating Amyotrophic Lateral Sclerosis and Symptoms |
WO2017160895A1 (en) * | 2016-03-15 | 2017-09-21 | Tyme, Inc. | Pharmaceutical compositions for the treatment of cancer |
EP3458071A1 (en) * | 2016-05-18 | 2019-03-27 | Tyme, Inc. | Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer |
CA3036511A1 (en) | 2016-09-12 | 2018-03-15 | Steven Hoffman | Compositions for treating dementia |
JP2019537608A (ja) | 2016-11-15 | 2019-12-26 | タイム,インコーポレーテッド | 癌の処置のための医薬組成物および方法 |
EP3548086A1 (en) | 2016-11-30 | 2019-10-09 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
WO2018195411A1 (en) | 2017-04-21 | 2018-10-25 | Steven Hoffman | Compositions and methods for treating retinopathy |
WO2018204669A1 (en) | 2017-05-03 | 2018-11-08 | Nanobio Corporation | Intravenous immunoglobulin compositions specific for respiratory syncytial virus and methods of making and using the same |
BR112020001074A2 (pt) | 2017-07-19 | 2020-07-14 | Hoffman Technologies, Inc. | composição |
JP2020534272A (ja) | 2017-09-15 | 2020-11-26 | タイム,インコーポレーテッド | 経皮製剤 |
WO2019130637A1 (ja) | 2017-12-28 | 2019-07-04 | ジェイファーマ株式会社 | がん治療薬 |
EP3820482A4 (en) | 2018-07-09 | 2022-03-23 | Tyme, Inc. | TUMOR REDUCING AGENT FORMULATIONS AND METHODS OF USE THEREOF |
US20210275467A1 (en) | 2018-07-09 | 2021-09-09 | Tyme, Inc | Tumor reduction formulations and methods of use thereof |
WO2020018292A1 (en) | 2018-07-19 | 2020-01-23 | Yamo Pharmaceuticals Llc | Compositions and methods for treating autism |
WO2020112766A1 (en) | 2018-11-26 | 2020-06-04 | Steven Hoffman | Compositions and methods for treating nerve agent exposure |
CN110563602A (zh) | 2018-12-26 | 2019-12-13 | 南宁多灵生物科技有限公司 | 迷迭香酸衍生物及其制备方法和应用 |
CN113710319A (zh) | 2019-02-01 | 2021-11-26 | 霍夫曼技术有限责任公司 | 用于治疗焦虑相关病症的组合物和方法 |
US20200282014A1 (en) | 2019-03-05 | 2020-09-10 | Hoffman Technologies Llc | Percutaneous anti-microbiota formulations |
WO2020197875A1 (en) | 2019-03-22 | 2020-10-01 | Tyme, Inc. | D-metyrosine compositions and methods for preparing same |
CN114901272A (zh) | 2019-04-19 | 2022-08-12 | 霍夫曼技术有限责任公司 | 持续释放制剂 |
MX2021013901A (es) | 2019-05-14 | 2022-04-12 | Tyme Inc | Composiciones y métodos para el tratamiento del cáncer. |
WO2021015437A1 (ko) | 2019-07-22 | 2021-01-28 | 고려대학교 산학협력단 | 활성산소 생성억제제 및 활성산소 소거제 복합물을 유효성분으로 포함하는 바이러스 감염 질환의 예방, 치료, 또는 개선용 조성물 |
CN114599352A (zh) | 2019-10-15 | 2022-06-07 | 迪美公司 | 用于治疗癌症的α-甲基-DL-酪氨酸烷基酯 |
IL293706A (en) | 2019-12-09 | 2022-08-01 | Tyme Inc | Pharmacy preparations and methods |
CA3167918A1 (en) | 2020-01-17 | 2021-07-22 | Tyme, Inc. | Compositions and methods for modulating cancer |
US20230165940A1 (en) | 2020-04-08 | 2023-06-01 | Hoffman Technologies Llc | Methods of treating conditions characterized by insulin deficiency in animals |
US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
WO2021231931A1 (en) | 2020-05-14 | 2021-11-18 | Tyme, Inc. | Methods of treating sars-cov-2 infections |
US20220002227A1 (en) | 2020-07-01 | 2022-01-06 | Tyme, Inc. | Crystalline forms of metyrosine |
-
2020
- 2020-05-14 MX MX2021013901A patent/MX2021013901A/es unknown
- 2020-05-14 BR BR112021022784A patent/BR112021022784A2/pt not_active Application Discontinuation
- 2020-05-14 KR KR1020217040394A patent/KR20220098682A/ko unknown
- 2020-05-14 JP JP2021567969A patent/JP2022532210A/ja active Pending
- 2020-05-14 WO PCT/US2020/032847 patent/WO2020232227A1/en unknown
- 2020-05-14 US US16/874,092 patent/US11534420B2/en active Active
- 2020-05-14 AU AU2020276605A patent/AU2020276605A1/en not_active Abandoned
- 2020-05-14 EA EA202193111A patent/EA202193111A1/ru unknown
- 2020-05-14 EP EP20805585.5A patent/EP3968785A4/en not_active Withdrawn
- 2020-05-14 CA CA3140042A patent/CA3140042A1/en active Pending
- 2020-05-14 CN CN202080050422.3A patent/CN114173578A/zh active Pending
-
2021
- 2021-11-10 IL IL287982A patent/IL287982A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021013901A (es) | 2022-04-12 |
US20200360328A1 (en) | 2020-11-19 |
WO2020232227A1 (en) | 2020-11-19 |
JP2022532210A (ja) | 2022-07-13 |
AU2020276605A1 (en) | 2022-01-20 |
EP3968785A4 (en) | 2023-01-11 |
EA202193111A1 (ru) | 2022-02-10 |
EP3968785A1 (en) | 2022-03-23 |
IL287982A (en) | 2022-01-01 |
US11534420B2 (en) | 2022-12-27 |
KR20220098682A (ko) | 2022-07-12 |
CA3140042A1 (en) | 2020-11-19 |
CN114173578A (zh) | 2022-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021022784A2 (pt) | Composições e métodos para tratamento do câncer | |
BR112018010089A2 (pt) | composições compreendendo cepas bacterianas | |
BR112018013065A2 (pt) | composições e métodos para o tratamento de hemoglobinopatias | |
CL2020002914A1 (es) | Métodos y composiciones para tratar el cáncer | |
BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
MD3209381T2 (ro) | Compoziții care conțin tulpini bacteriene | |
EA201991862A1 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
CL2018000198A1 (es) | Composiciones de arni de transtiretina (ttr) y métodos para su uso para el tratamiento o prevencion de enfermedades asociadas con ttr | |
EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
BR112019012062A2 (pt) | tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos | |
BR112018000776A2 (pt) | métodos para tratamento de câncer usando apilimod | |
BR112017000130A2 (pt) | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer | |
CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
BR112018069976A2 (pt) | anticorpo multiespecífico isolado ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, kit, e, método para tratamento de um indivíduo. | |
EA201991818A1 (ru) | Лечение рака | |
BR112019001398A2 (pt) | métodos para tratamento de câncer de próstata | |
PH12017501879A1 (en) | Methods for treating cancer | |
MX2020006297A (es) | Variantes de cd19. | |
BR112018075135A2 (pt) | combinações farmacêuticas para tratar câncer | |
PH12018501943A1 (en) | Pharmaceutical compositions for the treatment of cancer | |
BR112017009000A2 (pt) | apilimod para uso no tratamento de melanoma | |
EA202092824A1 (ru) | Комбинированная терапия | |
BR112014026813A2 (pt) | espaçadores de implante mamário para o tratamento de infecções de implante mamário periprostético | |
BR112018013928A2 (pt) | composições terapêuticas e métodos para tratamento da hepatite b | |
UY38472A (es) | Moduladores de la expresión de foxp3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |